BioPharma« Terug naar discussie overzicht

1. [verwijderd] 2 november 2006 14:18

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Ariad Pharm announces additional positive efficacy data on AP23573 - from further analysis of its ongoing Phase 2 (ARIA) 4.33 : Co announces additional positive efficacy data on AP23573-its novel mTOR inhibitor-from further analysis of its ongoing Phase 2 trial of AP23573 in patients with metastatic and/or unresectable bone and soft-tissue sarcomas. The expanded analysis focuses on the 61 patients with an AP23573 clinical-benefit response-the primary end-point of the 212-patient trial-and its relation to progression-free survival. Patients with an AP23573 clinical-benefit response-tumor regression or disease stabilization-had a progression-free survival rate at 6 months of 70% and a median P.F.S of 36 weeks. The P.F.S rate in this patient subset was nearly triple that of the overall trial population, and the median P.F.S was approximately 21 weeks longer than that of the overall trial population. These data show that C.B.R is a clinically useful surrogate for PFS in this difficult-to-treat patient population. These results are being presented by Dr. Sant Chawla, co-principal investigator of the study, at the 12th Annual Connective Tissue Oncology Society Meeting.
   
   finance.yahoo.com/marketupdate/inplay
2. [verwijderd] 3 november 2006 23:28

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   finance.yahoo.com/q?s=aria
   Valt goed.
   Slot op 4.65 + 0.16.
   Nabeurs nog doorgestegen tot 4.78
   Volgende week verder.
3. [verwijderd] 5 november 2006 10:51

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quotes.nasdaq.com/quote.dll?page=char...
4. [verwijderd] 5 november 2006 12:49

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Soms kan het zo maar zie grafiek
   geldt ook voor INSM
   
   finance.yahoo.com/q/bc?s=ARIA&t=my
5. [verwijderd] 5 november 2006 16:00

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Gisteren op Buy gezet bij Am Bulls
   
   www.americanbulls.com/StockPage.asp?C...
   
   Koers 4.65
   Koersdoel onbekend
6. Dereek 15 november 2006 19:41

   auteur info

   •    Dereek

     Lid sinds: 27 mrt 2002

     Laatste bezoek: 12 jul 2024

   •    Aanbevelingen

     Ontvangen: 12

     Gegeven: 7

   •    Aantal posts: 165

   Bertvv wat is hier aan de hand?
7. [verwijderd] 15 november 2006 19:47

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Ja welk koersdoel wat voor nieuws is er ????
8. [verwijderd] 15 november 2006 19:48

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   10% erbij zag ik.
   Rt 5.51
   Geen nieuws te vinden. Ik denk een inhaalslag.
   Gaat wel erg hard bijna $1 erbij in 2 dagen.
   messages.finance.yahoo.com/mb/ARIA
9. Dereek 21 februari 2007 00:13

   auteur info

   •    Dereek

     Lid sinds: 27 mrt 2002

     Laatste bezoek: 12 jul 2024

   •    Aanbevelingen

     Ontvangen: 12

     Gegeven: 7

   •    Aantal posts: 165

   vandaag ook weer eens lekker scoren met Ariad.
   heb het idee dat we morgen verder kunnen
10. [verwijderd] 30 maart 2007 16:36

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Gepikt van het Yahoo forum :
    
    In biology, signal transduction refers to any process by which a cell converts one kind of signal or stimulus into another, most often involving ordered sequences of biochemical reactions inside the cell, that are carried out by enzymes and linked through second messengers resulting in what is thought of as a "second messenger pathway". Such processes are usually rapid, lasting on the order of milliseconds in the case of ion flux, to minutes for the activation of protein and lipid mediated kinase cascades. In many signal transduction processes, the number of proteins and other molecules participating in these events increases as the process eminates from the initial stimulus, resulting in a "signal cascade" and often results in a relatively small stimulus eliciting a large response.
    
    Ariad Pharmaceuticals specializes in signal transduction pathways. Ariad has inside knowledge of the critical crossroads of the relative pathways.
    
    ARIAD’s initial Phase 3 clinical trial of oral AP23573 will be conducted in patients with metastatic soft-tissue and bone sarcomas by the Sarcoma Alliance for Research through Collaboration (SARC) in cooperation with the Soft Tissue and Bone Sarcoma Group of the European Organization for Research and Treatment of Cancer (EORTC). ARIAD has reached agreement with the U.S. Food and Drug Administration (FDA) on the design and endpoints of this pivotal trial and subsequently a Special Protocol Assessment (SPA) has been filed with the FDA for the trial based on the primary endpoint of progression-free survival (PFS). Similarly, a request for follow-up Protocol Assistance has been filed with the European Medicines Agency (EMEA). Patient enrollment is expected to begin as soon as agreement on the SPA is reached with the FDA, which is anticipated by early second quarter 2007.
    
    Commercial planning efforts are advancing for the potential launch of AP23573, as ARIAD pursues its strategy of achieving multiple oncology indications for this novel mTOR inhibitor. The Company is currently negotiating detailed terms with multiple pharmaceutical companies for a partnership to develop and commercialize AP23573 in a broad range of oncology indications and expects to complete the partnership agreement by the second quarter 2007.
    
    tinyurl.com/29yzsa